Ivacaftor (VX-770)

For research use only. Not for use in humans.

目录号:S1144 中文名称:依伐卡托

Ivacaftor (VX-770) Chemical Structure

CAS No. 873054-44-5

Ivacaftor (VX-770)是一种CFTR的选择性增强剂,靶向作用于G551D-CFTRF508del-CFTR,在fisher大鼠甲状腺细胞中EC50分别为100 nM和25 nM。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 919.69 现货
RMB 1374.83 现货
RMB 2608.67 现货
RMB 7957.63 现货
RMB 11384.1 现货
有超大折扣
今日订购,明日送达 全国免运费 分装免费
全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Ivacaftor (VX-770)发表文献183篇:

产品安全说明书

CFTR抑制剂选择性比较

生物活性

产品描述 Ivacaftor (VX-770)是一种CFTR的选择性增强剂,靶向作用于G551D-CFTRF508del-CFTR,在fisher大鼠甲状腺细胞中EC50分别为100 nM和25 nM。
特性 The first potent and orally available CFTR potentiator to enter human clinical trials.
靶点
F508del-CFTR [1]
(Fisher rat thyroid cells)
G551D-CFTR [1]
(Fisher rat thyroid cells)
25 nM(EC50) 100 nM(EC50)
体外研究

Ivacaftor(10 μM) 作用于表达CFTR突变型G551D的Fisher 大鼠甲状腺(FRT) 细胞,显著提高forskolin-刺激的Cl-分泌(IT),提高~4倍,EC50为100 nM,作用于表达CFTR突变型F508del进程的重组细胞,提高6倍,EC50为25 nM。与提高forskolin刺激的IT相一致,Ivacaftor(10 μM) 提高G551D-, F508del-, 和野生型CFTR 的开放概率(Po),分别提高~6倍,~5倍 和~2倍。说明Ivacaftor 直接作用于CFTR,而提高活性。Ivacaftor(10 μM)作用于携带G551D 和F508del CFTR 突变型的原代培养的人 CF 支气管上皮细胞(HBE),有效提高 forskolin-刺激的IT,提高10倍,从5%提高到最高水平48%,EC50为236 nM,有效性比通常使用的CFTR 增强剂Genistein高70多倍,EC50 为16 μM。Ivacaftor作用于携带F508del纯合子CFTR的HBE, 显著提高forskolin刺激的IT,EC50为22 nM, 从4%提高到16%。因为CFTR增强, Ivacaftor抑制过多ENaC-调节的Na+和液体吸收,IC50为43 nM, 且作用于G551D/F508del HBE,降低amiloride反应, 导致表面液体和纤毛摆动频率(CBF)提高。[1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HBE  NYSxSJJjTnWwY4Tpc44hSXO|YYm= NXvvb3I3OTBizszN NY\K[YNxOTBibXnu Ml7EZZVodWWwdIOgR2ZVWi2mZYDlcoRmdnRiaX;uJJRz[W6|cH;yeOKh NF[1SGY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEGwOlgxOSd-MkSxNFY5ODF:L3G+
CFBE41o- NGHHOGpHfW6ldHnvckBCe3OjeR?= NHTyeZAyOCEEtV2= NX;rWZlJcW6mdXPld{Bzd2K3c4SgbY5kemWjc3XzJIlvKGGwaX;uJJRz[W6|cH;yeC=> NUTCb41HRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK3OlgyOzBpPkKyO|Y5OTNyPD;hQi=>
HBE  MkHUSpVv[3Srb36gRZN{[Xl? MnvPNVAhyrWP NGjheoZifWevZX70d{BETlSULXTldIVv\GWwdDDhcolwdiC2cnHud5BwenRiYXP0bZZqfHl? NEK4eZA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mke2PFE{OCd-MkK3OlgyOzB:L3G+
HBE  MWjGeY5kfGmxbjDBd5NigQ>? M4e1[VExKML3TR?= MnvPNlQhcA>? NVjMWFJQcW6mdXPld{BiKG2xZHXzeEBjfXRic3nncolncWOjboSgbY5kemWjc3WgbY4hSVOOIHTldJRp MlvPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ5NkixN|AoRjJ{N{[4NVMxRC:jPh?=
HBE  NYXvfHU5TnWwY4Tpc44hSXO|YYm= M371VFExKML3TR?= MmLndI91\W62aXH0[ZMhS0[WUj3k[ZBmdmSnboSgTZNkNCC{ZXfhdoRt\XO|IH;mJJBzcW:{IHHkcYlvcXO2cnH0bY9vKG:oIFPTSS=> NFvTSYk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mke2PFE{OCd-MkK3OlgyOzB:L3G+
HBE  M1LqbmZ2dmO2aX;uJGF{e2G7 NEDuU5UyOCEEtV2= M1nPTpBienSrYXzsfUBz\XO2b4Lld{Bl\XCuZYTpc44hd2ZiQWPMJIRmeHSqIHnuJGNUTSC2cnXheIVlKG2xbn;sZZlmenN? NEDMZ2g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mke2PFE{OCd-MkK3OlgyOzB:L3G+
mouse NIH-3T3 cells NFrXNmtHfW6ldHnvckBie3OjeR?= NF;Ld5k{OCCvaX7z NU\4R49LWG:2ZX70bYF1cW:wIH;mJIh2dWGwIFPGWHIhTjVyOHTlcEBufXSjboSg[ZhxemW|c3XkJIlvKG2xdYPlJG5KUC1|VEOgZ4VtdHNiYX\0[ZIhOzBibXnud{BjgSCobIXvdoV{[2WwdDD2c4x1[WenIIPlcpNqdmdib4D0bYNidCCjc4PhfUwhTUN3MDC9JFAvODB|IN88UU4> MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR2MUCxN{c,OjV2NEGwNVM9N2F-
human bronchial epithelial cells Mk\SSpVv[3Srb36gZZN{[Xl? NYLp[3JKWG:2ZX70bYF1cW:wIH;mJIh2dWGwIFPGWHIhTjVyOHTlcE9IPTVzRDDteZRidnRiaX6gbJVu[W5iYoLvcoNpcWGuIHXwbZRp\WyrYXygZ4VtdHNiYomgWZN{cW6pIHPoZY1j\XK|IILlZ49z\GmwZzD0[YNpdmmzdXWsJGVEPTBiPTCwMlAzOiEQvF2u NGK1XIk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUS0NVAyOyd-MkW0OFExOTN:L3G+
human CFBE41o cells NYr5Z4Y{TnWwY4Tpc44h[XO|YYm= M1fETVExKG2rboO= MV7Qc5RmdnSrYYTpc44hd2ZiQ1\UVkBHPTB6ZHXsJI12fGGwdDCoeY5sdm:5bjDvdolocW5rIHX4dJJme3OnZDDpckBpfW2jbjDDSmJGPDGxIHPlcIx{KGmwY4XiZZRm\CCob4KgNVAhdWmwczDpckBxemW|ZX7j[UBw\iCob4Lzb49tcW5ibXXhd5Vz\WRiZn;yJFche2WlczDifUB[TlBiaHHsbYRmKGG|c3H5MEBGSzVyIE2gNE4yOjZizszNMi=> MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTF2OEe2N{c,OjlzNEi3OlM9N2F-
human bronchial epithelial cells NGi2XFlHfW6ldHnvckBie3OjeR?= NGfFU|FRd3SnboTpZZRqd25ib3[gbJVu[W5iQ1\UVkBHPTB6ZHXsJI12fGGwdDDpckBpfW2jbjDido9v[2irYXyg[ZBqfGinbHnhcEBk\WyuczDifUBWe3OrbnegZ4hidWKncoOgdoVkd3KmaX7nJJRm[2iwaYH1[UwhTUN3MDC9JFAvOjN4IN88UU4> MlLvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2NEGwNVMoRjJ3NESxNFE{RC:jPh?=
HEK293 cells NET6PHpHfW6ldHnvckBie3OjeR?= M3;kUlExKG2rboO= MV;Qc5RmdnSrYYTpc44hd2ZiQ1\UVkBIPTVzRDDteZRidnRiKIXub45wf25ib4Lp[4lvMSCneIDy[ZN{\WRiaX6gTGVMOjl|IHPlcIx{KGmwY4XiZZRm\CCob4KgNVAhdWmwczDpckBxemW|ZX7j[UBw\iCob4Lzb49tcW5ibXXhd5Vz\WRiZn;yJFIhdWmwczDifUB[TlBiaHHsbYRmKGG|c3H5MEBGSzVyIE2gNU4{KM7:TT6= NXHRd49xRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmxOFg4PjNpPkK5NVQ5PzZ|PD;hQi=>
NRK-49F cells MWDGeY5kfGmxbjDhd5NigQ>? NIraR|lKdmirYnn0bY9vKG:oIGTHSk1j\XSjMT3pcoR2[2WmIITveIFtKGOxbHzh[4VvKGGlY4XteYxifGmxbjDpckBz[XRiTmLLMVQ6TiClZXzsd{whUUN3MDC9JFQh|ryPLh?= MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR4N{G1O{c,OjV2NkexOVc9N2F-
DAOY cells NUHheXh3eUiWUzDhd5NigQ>? MX3xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDERW9[KGOnbHzz MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
NB-EBc1 cells MnzEdWhVWyCjc4PhfS=> MoLKdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgUmIuTUKlMTDj[Yxtew>? Mm\qQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
MG 63 (6-TG R) cells NVPXTWo1eUiWUzDhd5NigQ>? MYXxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDNS{A3OyBqNj3US{BTMSClZXzsdy=> MnfwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
RD cells MWDxTHRUKGG|c3H5 MXrxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDSSEBk\Wyucx?= MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
SK-N-MC cells MWPxTHRUKGG|c3H5 NHOyNYdyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBUUy2QLV3DJINmdGy| NX3Dc5FwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
Saos-2 cells M{fKOpFJXFNiYYPzZZk> NX6xTI8zeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhW2Gxcz2yJINmdGy| Ml;YQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
Rδf508; 

PubMed: 25101887     


Effect of VX-770 on the expression pattern of low temperature-rescued ΔF508-CFTR-3HA determined by immunoblot. Cells were treated with VX-770 alone for 24 hours at 26°C. CFTR was visualized with anti-HA antibody, and anti–Na+/K+-ATPase antibody served as loading control. 

NLRP3; 

PubMed: 30498130     


Immunoblotting with specific antibodies (NLRP3) in Caco-2 cells challenged for 2 or 4 h in the presence or absence of VX-770. NLRP3 expression.

PPARγ / pERK; 

PubMed: 30498130     


Caco-2 cells incubated with P31–43 in the presence or absence of VX-770. Immunoblot of PPARc or phospho-ERK1/2 (phERK1/2) and densitometric analysis of protein levels relative to b-actin.

25101887 30498130
Immunofluorescence
F-actin; 

PubMed: 30498130     


Confocal image staining with anti-F-actin. DAPI (blue), nuclear counterstaining. Scale bar, 50 μm.

30498130
体内研究 Ivacaftor作用于携带G551D突变的,年龄6到11的囊性纤维化对象,已经完成三期研究。

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

溶解度 (25°C)

体外 DMSO 78 mg/mL (198.73 mM)
Water Insoluble
Ethanol Insoluble

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 392.49
化学式

C24H28N2O3

CAS号 873054-44-5
储存条件 粉状
溶于溶剂
别名 N/A

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04254705 Not yet recruiting Procedure: Rectal Biopsy Cystic Fibrosis Universitaire Ziekenhuizen Leuven|Vertex Pharmaceuticals Incorporated|KU Leuven|University of Lisbon March 1 2020 Not Applicable
NCT03085485 Recruiting Drug: Ivacaftor 150 MG|Drug: Placebo Chronic Obstructive Pulmonary Disease|Chronic Bronchitis University of Alabama at Birmingham|National Heart Lung and Blood Institute (NHLBI)|Vertex Pharmaceuticals Incorporated March 16 2017 Phase 2
NCT02724527 Unknown status Drug: Cavosonstat|Drug: Placebo Cystic Fibrosis Nivalis Therapeutics Inc. April 2016 Phase 2
NCT02725567 Recruiting Drug: ivacaftor Cystic Fibrosis Vertex Pharmaceuticals Incorporated March 2016 Phase 3

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

CFTR Signaling Pathway Map

相关CFTR产品

Tags: 购买Ivacaftor (VX-770) | Ivacaftor (VX-770) ic50 | Ivacaftor (VX-770)价格 | Ivacaftor (VX-770) DMSO溶解度 | 采购Ivacaftor (VX-770) | Ivacaftor (VX-770)生产 | Ivacaftor (VX-770) 小鼠 | Ivacaftor (VX-770)化学结构 | Ivacaftor (VX-770)分子量 | Ivacaftor (VX-770) molecular weight | Ivacaftor (VX-770)说明书 | Ivacaftor (VX-770)供应商 | Ivacaftor (VX-770)体内 | Ivacaftor (VX-770)细胞系 | Ivacaftor (VX-770)浓度 | Ivacaftor (VX-770) nmr | Ivacaftor (VX-770)核磁 | Ivacaftor (VX-770)半数抑制浓度 | Ivacaftor (VX-770)体外
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID